Research & Development

Advamedica foresees contemporary integrated knowledge in biomaterials, medicine, and engineering with the aim of designing novel solutions in the not-too-distant future. This will also help in addressing the unmet needs in the management of trauma and chronic infectious wounds.

Advamedica envisages a future where contemporary knowledge of biomaterials, medicine and engineering will be integrated in designing novel solutions to address the huge unmet need in management of trauma and chronic-infectious wounds.

We are a deep science medtech company with extensive R&D expertise in biomaterials. Our platform-based approach enables us to develop medical products that are engineered to enhance its efficacy even at higher scale. With such a vision, we introduced our first line of haemostatic products that are probably one of the best available trauma heamostats in the market today.

Advamedica’s research philosophy is to translate the biomaterials research into real-world products and bring them to patients’ bedside at an affordable cost. Here innovation is a daily practice as we explore unchartered territories in novel materials and technologies. The research & development team at Advamedica is developing novel solutions that are smarter, friendlier and quicker than the conventional products.

Non-woven Biomaterial Fibers

SEM image of biomaterial fibers on novel hemostat

Dual-action Hemostat

Cross-section of biomaterial sponge sandwiched with non-woven fibers using proprietary technology

Biomaterial Sponge

SEM image showing honeycomb like uniform porous structure

Advancing biomaterial innovations to deliver the next generation of advanced wound care and hemostatic products. We are a deep science-driven MedTech company. We strive to help patients heal faster and get better.

Our Approach to R&D

At Advamedica, we have a unique approach to our Research and Development (R&D) to strengthen our pipeline and unlock potential in the emerging fields of healthcare. We focus on biomaterial science, the use of natural and synthetic biomaterials and is driven by the amalgamation of advanced cutting edge technologies, biomaterial science and agile methodologies. It helps us to accelerate the pace at which we innovate, develop and deliver our most promising assets to serve the greatest unmet medical need. Our innovation ambition is to lead Advamedica and become the pioneers among Indian Med Tech companies by disrupting the discovery, development, manufacturing, and deliver the breakthrough products.

Our R&D core strength lies in our ability to excel in developing the most promising medical device products through interdisciplinary teams in product formulations, process chemistry, and analytical development. We have the strong capability to deliver the best quality products within specified timelines, at low costs, and without compromising on product quality. Over the years, our R&D department has developed expertise and gathered experience in performing device invitro and invivo characterization studies, biocompatibility studies, Cellular studies, preclinical and clinical studies with standard model and protocol according to USFDA, ISO, and ASTM guidelines.

Expertise and Experienced R&D Team

In Advamedica, our R&D team continuously managed to push the boundaries in biomaterial science, including the development of advanced haemostat, next-generation wound care dressing, PPH management device, surgical tissue adhesive, sealant, scaffolds by tissue engineering as well as the introduction of a variety of personal hygienic products as COVID essentials and skincare products with the goal to improve the quality of patient’s lives and longer live of people.

We have 10+ research scientists with multiple PhDs, Post Docs working in our R&D center equipped with advanced lab instruments, cutting-edge enabling technologies for research and 5S lab system. Our scientists have expertise in biomaterial research that allows rapid development of a basket of robust medical device products for diverse healthcare market across the world.

Intellectual Property

Our innovative research strategy and implementation are well supported by a strong and established intellectual property team having expertise and experience in biomaterial science, Synthetic and process chemistry, analytical techniques, dosage forms, and global patent law. Over the last 5 years, we have been consistently successful in challenging patents on several high-value products globally.

R&D Pipeline

Our Healthcare R&D organization focuses mainly on three categories: Advanced hemostats, next-generation wound care dressing, and personal hygiene and protection. Our R&D focus is on building a strong, competitive pipeline of consumer-led med-tech products based on biomaterial science innovation. We are focusing on accelerating key assets in our pipeline and looking at cutting-edge med-tech technologies to save more patient’s life through expanding indications and delivering innovative healthcare products to new geographies. The multiplier effect of our well-structured product pipeline, Continued advancement of technologies, and a better understanding of biomaterial science helps us to explore new breakthroughs and resolve the world’s biggest health challenges.

Ø Hemostasis

Ø Wound Care

Ø Mucoadhesive Delivery

Ø Tissue Engineering and Biomaterials based Scaffolds

Dr. Mahadevan is a Professor of Emergency Medicine at Stanford University where he has been a recipient of numerous teaching awards. He also serves as the Director of Global Affairs and Strategy for Stanford Medicine. He received his medical degree from David Geffen School of Medicine at UCLA.

Dr. Sengupta serves as the Associate Professor of Medicine at HMS and as the Associate Professor of Health Sciences and Technology at MIT. Dr. Sengupta received his PhD from University of Cambridge as a British Chevening and Nehru Scholar, and is a recipient of the TR35 Innovator Award from the MIT Technology Review Magazine and the Era of Hope Scholar Award from the US Department of Defense.

Satish brings a wealth of diverse experiences to his CFO role at Advamedica. In addition to his Fortune 500 roles (FedEx, Citi, AmEx, JPM Chase) in various leadership capacities across multiple countries, he has worked with a number of startups and SMBs as their in-house or consulting CFO. Satish has held CFO roles in a number of verticals ranging from education to healthcare and technology companies. In these roles Satish was in charge of all areas of finance including strategy, fundraising, board and investor reporting as well as M&A. Over the last three years Satish has helped companies raise over $100 million in venture capital and financing.

Quality professional with over 25 years of experience in the medical device, pharmaceutical, and software industries.
Maria is specialized in developing and implementing Quality Management Systems and has deep knowledge and experience in audit preparation, resolution/remediation as per regulatory compliance in ISO 13485, 21 CFR Part 820, EU MDR, MDSAP, and other regional regulations (China, Taiwan, Brazil, Japan, Canada, Australia, Korea, Switzerland, etc.)

Samantha is Director of Clinical Marketing at Advamedica. Previously she was Global Training Manager in Terumo Aortic overseeing all training and clinical skills to support their latest endovascular technology. Prior to that Samantha was National Sales & Marketing Manager in Bolton Medical, Italy for almost a decade. She started her career as a OR Nurse before moving to the Medical Devices field. Samantha has done Executive MBA in Strategic marketing and has Degree in Professional nursing from University of Bologna, Italy.

Edward is US – National Sales Director at Advamedica. He comes with many decades of experience selling novel hemostats and woundcare products in over 26 states in the US. He was earlier Regional Sales Director at Z-Medica managing business of their Hemostatic product line to Surgery, Trauma, Critical Care, Cardiology, Emergency Room, Cath Lab / Interventional Radiology, Burn and Wound Care. Prior to that he was responsible for managing Allograft business as Area Business Manager at MTF Biologics. He is passionate about creating top performing teams, driven by diversity, inclusion, values and accountability. Expertise in sales force effectiveness, process initiatives, and personnel management. Edward has a Bachelor of Business Administration from Dowling College.

Oscar Rospigliosi is a Senior MedTech executive with broad experience in medical device sales and marketing. He was the CEO & Director at Scion Biomedical and prior to that he was a CEO at Bolton Medical Group, guiding the company from $4.5mn in annual revenues to $80mn in cardio-thoracic market. With the introduction of a unique abdominal stent graft product line, Mr. Rospigliosi was able to drive sales to over $50Mn with greater than 10% growth year over year.

Leo Mavely is the president of Advamedica Inc. He is passionate about medtech innovations for unmet healthcare needs, and has been featured by Fortune Magazine in 40 under 40 business leaders and by Entrepreneur Magazine in 35 under 35 Game-Changing Entrepreneurs. He holds a Bachelor’s degree in Bioengineering.


If you continue, you will leave this site and go to a non-US site.

Some of the products on the other site may not be approved in the United States.”

Contact us


If you continue, you will leave this site and go to a non-US site.

Some of the products on the other site may not be approved in the United States.”